Leaving behind its much anticipated collaboration with Pfizer, Allergan inked an R&D and commercialisation agreement to acquire global rights to Heptares Therapeutics’ novel G protein-coupled receptor (GPCR) targeted therapies for Alzheimer’s disease and other cognitive and psychotic disorders. The deal involving M1, M4 and dual M1/M4 subtype specific muscarinic agonists is worth US$3.34 B and includes an upfront payment of US$125 M. With this agreement, Allergan will be hoping to bolster its central nervous system pipeline with innovative clinical stage drugs.